Background Human immunodeficiency virus (HIV)-infected patients are at increased risk of liverrelated mortality. The effect of occult cirrhosis (OcC), defined as preclinical compensated cirrhosis without any clinical findings, on liver-related events is unknown. Methods HIV-infected patients from two Canadian cohorts underwent transient elastography (TE) examination and were classified as: 1) OcC (TE ≥13 kPa with no sign of cirrhosis, including absence of thrombocytopenia and signs of advanced liver disease on ultrasound or gastroscopy); 2) overt cirrhosis (OvC) (TE ≥13 kPa with signs of cirrhosis); 3) non-cirrhotic patients (TE <13 kPa). Incidence and risk factors of liverrelated events were investigated through Kaplan-Meier and Cox regression analyses, respectively. We estimated monitoring rates according to screening guidelines for hepatocellular carcinoma (HCC) by OcC and OvC status. Results 1092 HIV-infected patients (51% coinfected with hepatitis C virus) were included. Prevalence of OcC and OvC at baseline was 2.7% and 10.7%, respectively. During a median follow-up of 1.8 (interquartile range: 1.5-2.8) years, the incidence of liverrelated events in non cirrhotics, OcC, and OvC was 3. 
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Abstract
Background
Human immunodeficiency virus (HIV)-infected patients are at increased risk of liver-related mortality. The effect of occult cirrhosis (OcC), defined as preclinical compensated cirrhosis without any clinical findings, on liver-related events is unknown.
Methods
HIV-infected patients from two Canadian cohorts underwent transient elastography (TE)
examination and were classified as: 1) OcC (TE ≥13 kPa with no sign of cirrhosis, including absence of thrombocytopenia and signs of advanced liver disease on ultrasound or gastroscopy);
2) overt cirrhosis (OvC) (TE ≥13 kPa with signs of cirrhosis); 3) non-cirrhotic patients (TE <13 kPa). Incidence and risk factors of liver-related events were investigated through Kaplan-Meier and Cox regression analyses, respectively. We estimated monitoring rates according to screening guidelines for hepatocellular carcinoma (HCC) by OcC and OvC status.
Results
HIV-infected patients (51% coinfected with hepatitis C virus) were included. Prevalence of
OcC and OvC at baseline was 2.7% and 10.7%, respectively. During a median follow-up of 1.8 (interquartile range: 1.5-2.8) years, the incidence of liver-related events in non cirrhotics, OcC, 
Introduction
Liver disease is the leading cause of non-AIDS related deaths in people living with the human immunodeficiency virus (HIV) [1] . HIV-infected individuals have multiple risk factors for liver injury, including coinfections with hepatitis C (HCV) and B (HBV) viruses, metabolic conditions triggering non-alcoholic fatty liver disease (NAFLD), excessive alcohol intake, and antiretroviral therapy (ART) inducing hepatotoxicity [2, 3] . This hypothetical multi-hit process can then lead to cirrhosis, hepatocellular carcinoma (HCC), and complications associated with end-stage liver disease (ESLD) such as ascites, hepatic encephalopathy, and variceal bleeding [4] . Up to 63% of patients with liver disease are diagnosed with liver cirrhosis only at the first episode of hepatic decompensation [5] . Therefore, identifying patients with underlying liver cirrhosis is critical as surveillance for HCC and esophageal varices can be promptly initiated [6] .
A major obstacle to the diagnosis of cirrhosis at the preclinical stage, also known as occult cirrhosis (OcC), is the lack of any clinical, laboratory and imaging findings. Patients with OcC do not have thrombocytopenia and have no features consistent with cirrhosis on imaging.
Nonetheless, OcC is identified in up to 12% of patients referred for transient elastography (TE) examination and it accounts for up to 37% of all cirrhosis cases [7, 8] . HIV-negative patients with OcC are at risk of developing ESLD events, but they receive suboptimal surveillance for HCC when compared to patients with clinically overt cirrhosis (OvC) [7] [8] [9] .
Liver biopsy is the gold standard for the diagnosis of liver cirrhosis but it is invasive and prone to sampling errors leading to the misdiagnosis of cirrhosis [10] [11] [12] . As such, it is unpractical as a screening tool or for the follow-up of HIV-infected patients, where the prevalence of liver 5 disease is high [13] . The measurement of liver stiffness (LSM) by TE is a validated non-invasive method to diagnose liver cirrhosis, with a reported area under the curve of 0.94 [14] . TE is superior to simple fibrosis biomarkers, including the aspartate to platelet ratio index (APRI) and the fibrosis-4 score (FIB-4), in HIV-infected patients infected [15] [16] [17] .
Thus far, the prevalence of OcC in HIV-infected patients and its impact on incident liver-related events has not been reported. We used data from two large clinical Canadian cohorts to fulfill the following aims: (i) determine the prevalence and associated factors of OcC diagnosed by TE; (ii) evaluate the incidence of liver-related events in patients with OcC; and (iii) investigate monitoring rates, according to guidelines, for screening of HCC in patients with OcC.
Patients and methods
Study design and population
We conducted a retrospective analysis of the Canadian Coinfection Cohort (CCC) and the LIVEr in HIV (LIVEHIV) studies [18, 19] . The CCC is a prospective cohort of patients co-infected with HIV and HCV enrolled at 18 centres across Canada where they are followed-up every 6 months 
Eligibility
All consecutive HIV-infected adults aged ≥18 years were eligible. Patients in the CCC who were enrolled in centres not participating in the FibroScan sub-study were excluded. Patients with failure of TE examination or unreliable LSM were also excluded.
Clinical and biological parameters
Data collected included demographic information, HIV and medications history, body mass index (BMI), history of type 2 diabetes mellitus [20] , liver biochemistries, hematological and virological parameters. Alcohol intake was measured by the Alcohol Use Disorders Identification Test (AUDIT-C) questionnaire, with a score ≥4 for men and ≥3 for women considered as hazardous alcohol intake [21] . The following fibrosis biomarkers were computed: APRI (with a cut-off value ≥2 suggesting liver cirrhosis); FIB-4 (with a cut-off value ≥3.25 suggesting advanced liver fibrosis) [17, 22] . Results of abdominal imaging and gastroscopies were recorded.
TE examination
The TE examination was performed in patients fasting for at least 3 hours. The standard M probe was used in all patients. The XL probe was used in cases of failure of TE with the M probe or if the BMI was greater than 30 kg/m 2 . The following criteria were applied to define the result of TE as reliable: at least 10 validated LSM, and an interquartile range (IQR) <30% of the median LSM [23] . Hepatic steatosis measurement by controlled attenuation parameter (CAP) was available in the LIVEHIV Cohort. Any grade hepatic steatosis (>5% of hepatocytes) was defined as CAP ≥288 decibels per meter (dB/m) [24] .
Definition of study groups
Patients were divided into four mutually exclusive subgroups. chosen based on a meta-analysis [14] .
Outcome measures
Liver-related events were prospectively collected by means of a dedicated outcome measures form. Liver-related events included occurrence of de novo ascites, variceal bleeding or banding, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy, HCC, liver transplantation, and death from liver-related causes. Screening interval for HCC was defined as receiving abdominal imaging at least every 12 months during the study period [26, 27] .
Follow-up
Patients were followed from their first TE examination (baseline, or time zero) until they had a liver-related event, died, withdrew consent, were lost to follow-up (no visits for more than 1.5 years), or until administrative censoring (March 31, 2017 for the CCC and on January 14, 2017 for the LIVEHIV cohort). Non liver-related deaths were censored. The decision to initiate surveillance for HCC was left to the treating physician.
Statistical analysis
Cross-sectional component
The period prevalence was reported as the ratio of the total number of prevalent and incident cases to the total number of patients included in the study. The association between various risk factors at inclusion and prevalent or incident OcC -among patients at risk for OcC -were assessed using a cross-sectional approach with unadjusted and adjusted logistic regression models. We reported results as adjusted odds ratios (aOR). Due to the cross-sectional nature of any such measured associations, we made no causal claims from these analyses.
Longitudinal component
Kaplan-Meier plots were used to show the cumulative incidences over time, as stratified by study group and coinfection status, using the log-rank test to test for differences between groups. The association between various risk factors and the incidence of de novo liver-related events were assessed with unadjusted and adjusted Cox proportional hazards models. Results were reported as adjusted hazard ratios (aHR) with 95% confidence intervals (CI). Finally, as an exploratory analysis, the proportion of patients -among those at risk for HCC -with adequate cirrhosis surveillance were reported descriptively and stratified by study group. The same analysis was stratified by source cohort and by HCV coinfection status. A two-sided level of significance of 5% was used for all statistical inferences.
Covariates
All adjusted regression models included covariates that were determined a priori to be clinically important; this list was further restricted due to limited event counts. The following baseline covariates were chosen: age, sex, aboriginal ethnicity, hazardous alcohol intake in past year, BMI, diabetes in past year, lipid lowering therapy in past year, nadir CD4 count, detectable HIV RNA in past year, HCV RNA positive, HIV duration and ART duration. Where multiple models were estimated for the same outcome, the model with the best goodness-to-fit measure, based on the Akaike Information Criteria (AIC), was chosen.
Results
After applying the inclusion and exclusion criteria, 1092 HIV-infected individuals were included, of whom 499 were HIV monoinfected, 556 were HIV/HCV coinfected and 37 were HIV/HBV coinfected ( Figure 1 ). Failed or unreliable LSM comprised 7.0% of patients from the CCC and 5.8% of patients from the LIVEHIV cohort.
Prevalence, incidence and factors associated with occult cirrhosis
OcC and OvC represented 2.7% and 10.7% of our study population, respectively. OcC patients represented 19.9% of all patients with cirrhosis. The main characteristics by study group status at baseline are presented in Table 1 . Figure 2 and Supplemental Table S1 Table 2) . We also observed a tendency for higher BMI to be a factor associated with OcC.
Incidence and risk factors of liver-related events
The overall incidence of liver-related events was 8.6 (95% CI: 4.9-14.0) per 1000 PY, mainly driven by the occurrence of de novo ascites and HCC (Table 3 ). The incidence rate of liverrelated events was similar between patients with OcC and OvC (Table 3 ; Figure 3c ). Conversely, non-cirrhotic patients had a very low incidence of liver-related events, while patients with noncirrhotic portal hypertension had an intermediate incidence. HCV coinfection showed a tendency to be associated with an increased incidence of liver-related events (Figure 3d ). (HIV/HBV coinfected) with OcC developed HCC during the follow-up, accounting for an incidence of 15 per 1000 PY. At diagnosis, there were two lesions consistent with HCC, with the largest one measuring 6 cm and the smaller one 3 cm. This tumor was beyond any transplant criteria, including Milan Criteria, total tumor volume, Up-to-Seven, and UCSF criteria [28] . The patient was offered TACE and Sorafenib but declined. He died 7.8 months after the diagnosis. In the OvC group, the 3 patients who developed HCC were HIV/HCV coinfected and were diagnosed at an earlier stage (single lesion ranging from 1.7 to 3.2 cm). They were offered transarterial chemoembolization (n=1) or liver transplant (n=2) and are still alive.
Discussion
In this well-characterized clinical cohort, we showed that OcC is a frequent occurrence, representing nearly 20% of all patients with liver cirrhosis in HIV-infected individuals. We also showed that liver-related events had similar incidence rates in HIV-infected patients with OcC and OvC, rendering essential for the HIV clinician to be aware of this clinical entity. Finally, patients with OcC do not receive screening at recommended intervals for detection of important ESLD complications, specifically HCC, which may result in a late diagnosis.
Until recently, the description of a liver as "cirrhotic" was sufficient to define patients'
prognosis. Garcia-Tsao et al suggested that cirrhosis is rather a dynamic condition encompassing a more complex clinicopathological spectrum [29] . Given the lack of any clinical sign, patients at the preclinical stage of compensated cirrhosis represent a diagnostic challenge for clinicians, and often remain undiagnosed. The diagnosis of OcC based on LSM and the absence of clinical signs has previously been shown, in different patient populations, to be an indicator of poor prognosis [7, 9] . Individuals living with HIV are known to be at increased risk of liver cirrhosis and ESLD [1] . Our study is the first to report on the prevalence of OcC and its impact on liverrelated events in HIV-infected patients.
In our large combined cohort of 1092 HIV-infected patients, OcC was found in 2.7% of cases, prevalence similar to that reported in other populations [7, 9] . Although seemingly comprising only a small proportion of patients at baseline TE, the prevalence of OcC increased to 3.9% during the follow-up period, with an annual incidence rate of 10 per 1000 PY. These changes in LSM may herald a poor prognosis, as reported in other patient populations [30] [31] [32] .
14 The only independent factor associated with OcC at baseline vs. non-cirrhotic subgroup was longer duration of HIV infection, which is a proxy for exposure to multiple hepatotoxic hits [18] .
Interestingly, HCV coinfection was not associated with an increased prevalence or incidence of
OcC, but rather with the development of OvC. This could be explained by either a faster progression of HCV coinfected patients from earlier stage of liver disease to OvC[33] or because they are more frequently monitored with TE, and thus diagnosed more often. Higher BMI had a trend in being an independent risk factor for OcC, thus confirming the emerging concern around NAFLD in HIV-infected patients [18, 34] . Accordingly, hepatic steatosis diagnosed by CAP had the highest frequency in the OcC group (27%). Taken together, our findings suggest that clinicians should suspect OcC in patients with longer HIV infection and higher BMI even in absence of any sign of liver cirrhosis. Moreover, screening for liver cirrhosis should not be limited to HIV patients coinfected with HCV, as multiple risk factors may still be driving progressive liver fibrosis and we would miss important opportunities to prevent liver decompensation.
Patients with OcC were more likely to develop a liver-related event when compared to patients without cirrhosis, with a 10 times higher incidence rate. On the other hand, the incidence of a liver-related event was similar between those with OcC and OvC. Our findings are similar to a previous study by Merchante and colleagues where patients with cirrhosis had an incidence of Our study has several strengths. To our knowledge, it is the first study characterizing risk factors and dynamics of liver cirrhosis in its preclinical stage in HIV-infected patients. It relies on two prospectively maintained large cohorts of consecutive individuals living with HIV. We employed an accurate and validated non-invasive tool to diagnose liver cirrhosis [13, 40] . We wish to acknowledge several limitations of our study. First, although we included a large number of patients, the follow-up period was relatively short. We observed a limited number of clinical outcomes and thus our estimates of incidence rates are imprecise. However, our findings showed that OcC patients behave as those with OvC in case of HIV infection. Second, because a crosssectional approach was used to determine factors associated with OcC, no inferential conclusions can be derived. However, these associated factors could help identify who might be prioritized for screening. Third, we did not have data about the indication for ultrasound, which could have been performed for reasons other than HCC screening. Fourth, there is a potential for competing risk from death from other causes. Fifth, liver biopsy was not available in our study. However, we validated our findings longitudinally by demonstrating that OcC group had worse clinical outcomes than the non-cirrhotic group. Using liver biopsy in our cohort of more than 1,000 patients would not have been feasible.
In conclusion, OcC accounts for 1 in 5 cases of cirrhosis in HIV-infected patients. These patients, whether HCV coinfected or not, constitute a high-risk group prone to liver-related events. We advocate that HIV-infected patients with OcC should receive surveillance for HCC to the same degree as patients with OvC. Screening for cirrhosis with point of care non-invasive diagnostic tools, such as TE, should be considered in HIV-infected patients, especially in case of long duration of HIV infection and higher BMI.
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[2] Liver stiffness measures by TE were considered reliable if the ratio of the IQR over the median of the 10 measures was no more than 30%. 
